Skip to content

    Ovarian Cancer Health Center

    Font Size

    Ovarian Epithelial Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Changes to This Summary (06 / 24 / 2014)

    The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

    General Information About Ovarian Epithelial Cancer

    Added text to state that findings from risk-reducing surgeries in healthy women with BRCA1/2 mutations have reinforced the hypothesis that many high-grade serous cancers may arise from precursor lesions that originate in the fimbriae of the fallopian tubes (cited Levanon et al. as reference 5). Also added that histologically similar cancers diagnosed as primary peritoneal carcinomas share molecular findings, such as loss or inactivation of the tumor-suppressors p53 and BRCA1/2 proteins; therefore, high-grade serous adenocarcinomas arising from the fallopian tube and elsewhere in the peritoneal cavity, together with most ovarian epithelial cancers, represent "extrauterine adenocarcinomas of Müllerian epithelial origin" and are staged and treated similarly to ovarian cancer. On the other hand, clear cell and endometrioid ovarian cancers that are linked to endometriosis have different gene-expression signatures, as do mucinous subtypes (cited Birrer as reference 6).

    Stage I and Stage II Ovarian Epithelial Cancer Treatment

    Added text to state that patients with stage II ovarian cancer were also enrolled in a Japanese Gynecology Oncology Group (JGOG) study that tested a weekly dosing schedule versus the conventional every-3-week dosing schedule in first-line ovarian cancer (cited 2009 Katsumata et al., 2013 Katsumata et al., and Scambia et al. as references 16, 17, and 18, respectively).

    Stage III and Stage IV Ovarian Epithelial Cancer Treatment

    Added text to state that a JGOG trial circumvented the standard treatment trend and included patients with stage II through stage IV disease in addition to the patients undergoing neoadjuvant therapy. Also added that with results initially published in 2009 and long-term results updated in 2013, the JGOG-3601 trial has stimulated a number of other trials that address weekly dosing schedules versus the conventional every-3-week dosing in first-line epithelial ovarian cancer (cited 2009 Katsumata et al., 2013 Katsumata et al., and Scambia et al. as references 6, 7, and 8, respectively). Also added that, conducted between 2003 and 2006, the Japanese trial accrued 637 patients and randomly assigned them to a range of six to nine cycles of the weekly 80 mg/m2 of paclitaxel versus the usual intermittent schedule of paclitaxel at 180 mg/m2; both regimens were given with carboplatin (area under the curve 6) in every-3-weeks cycles. With a primary endpoint of progression-free survival (PFS), an increase from 16 to 21 months in the PFS of the weekly paclitaxel-based regimen was sought.

    1 | 2
    Next Article:

    Today on WebMD

    Ovarian cancer illustration
    What are the symptoms?
    doctory with x-ray
    Get to know the symptoms.
    cancer cell
    HPV is the top cause. Find out more.
    Lung cancer xray
    See it in pictures, plus read the facts.
    Integrative Medicine Cancer Quiz
    Lifestyle Tips for Depression Slideshow
    Screening Tests for Women
    Graphic of ovaries within reproductive system
    Ovarian Cancer Marker
    Pets Improve Your Health
    Vitamin D
    Healthy meal with salmon